Contact information
Peter Scanlon
MD FRCP FRCOphth FHEA DCH DRCOG DO
Associate Professor
- Tutor and Senior Research Fellow, Harris Manchester College
Prof. Peter Scanlon has been Clinical Director for the English NHS Diabetic Eye Screening Programme since 2003, and he has, with the support and co-operation of colleagues, moved screening from limited ad hoc delivery of services to systematic quality assured processes for screening, assessment and treatment across all of England to 2.3 million people with diabetes. Dr Scanlon also holds an appointment as a Senior Research Fellow and Medical Tutor at Harris Manchester College, University of Oxford, and as Visiting Professor at the University of Gloucestershire. Dr Scanlon is Lead Author of the textbook ‘Practical Manual of Diabetic Retinopathy Management’ and has written the Diabetic Retinopathy Chapter for the Textbook of Diabetes, 4th Edition (both Wiley Blackwell).
His research interests lie in the Screening, Epidemiology, Assessment and Treatment of Diabetic Retinopathy and he has published extensively in these areas.
Recent publications
-
Disengagement and loss to follow-up in intravitreal injection clinics for neovascular age-related macular degeneration.
Journal article
Jones R. et al, (2023), Eye (Lond)
-
Developing decision support tools incorporating personalised predictions of likely visual benefit versus harm for cataract surgery: research programme
Journal article
Sparrow JM. et al, (2022), Programme Grants for Applied Research, 10, 1 - 54
-
Assessing the impact of COVID-19 on visual acuity for diabetic macular edema patients treated with aflibercept in the UK
Conference paper
Scanlon PH. et al, (2022), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 63
-
The impact of COVID-19 on visual acuity for nAMD patients treated with aflibercept in the UK
Conference paper
Bailey C. et al, (2022), INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 63
-
Improving the screening of risk factors in diabetic retinopathy.
Journal article
Scanlon PH., (2022), Expert Rev Endocrinol Metab, 17, 235 - 243